Perspective Therapeutics, Inc. (New York Stock Exchange Arca:CATX)
| Market Cap | $91.03M-65.3% |
| Revenue (ttm) | $177.00K-79.6% |
| Net Income | -$122.91M-19.6% |
| EPS | -$1.24+13.2% |
| Shares Out | 120.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,391,469 |
| Open | $0.76 |
| Previous Close | $0.78 |
| Day's Range | $0.74 - $0.79 |
| 52-Week Range | $0.73 - $6.16 |
| Beta | 1.99 |
| Analysts | Buy |
| Price Target | $7.50(+894.96%) |
| Earnings Date | Mar 15, 2027 |
About CATX
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Perspective Therapeutics, Inc. Stock Analysis — InsiderScore
Perspective Therapeutics, Inc. scored higher than 52% of companies evaluated by InsiderBuying, and ranked 38th out of 108 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Perspective Therapeutics, Inc. bought $175.4K of stock across 10 purchases in the last 90 days, the largest of them $37.9K.
The average purchase added about 59% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
5 firms rating CATX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 15, 2027Earnings report
$CATX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CATX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CATX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CATX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CATX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CATX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CATX
| VTIVanguard Morningstar Total Stock Market ETF | $2.96M |
| IWMiShares Russell 2000 ETF | $2.09M |
| VXFVanguard Extended Market ETF | $1.14M |
| IWNiShares Russell 2000 Value ETF | $764.87K |
| VTWOVanguard Russell 2000 ETF | $694.85K |
| IBBiShares Biotechnology ETF | $549.98K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CATX’s recent data — informational, not investment advice
What’s Behind the Score
News check: BofA slashed price target 80% while Wedbush cut guidance; Q3 results reported amid analyst downgrades signal fundamental challenges.
Recent Insider Activity
Insider Score Trend Over Time
+68.5 since Sep 3Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
